Landiolol in supraventricular tachycardia: an updated review of clinical applications

Natarajan Thangam Nivasini; P. V. Karthik; Arunkumar R.; Vikram Balaji; Kala P.; Jamuna Rani R.

doi:10.18203/2319-2003.ijbcp20252591

Authors

Natarajan Thangam Nivasini Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kanchipuram, Chennai, Tamil Nadu, India
P. V. Karthik Parvathy Institute of Cardiac Sciences Parvathy Hospital, Chrompet, Chennai, Tamil Nadu, India https://orcid.org/0009-0001-6909-3546
Arunkumar R. Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kanchipuram, Chennai, Tamil Nadu, India https://orcid.org/0009-0007-0935-2001
Vikram Balaji Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kanchipuram, Chennai, Tamil Nadu, India https://orcid.org/0009-0008-3818-047X
Kala P. Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kanchipuram, Chennai, Tamil Nadu, India https://orcid.org/0000-0002-9694-3024
Jamuna Rani R. Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kanchipuram, Chennai, Tamil Nadu, India https://orcid.org/0000-0002-2797-7888

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20252591

Keywords:

Landiolol, Supraventricular tachycardia, Beta-blockers, Atrial fibrillation, Cardiac arrhythmia, Ultra-short-acting beta-blocker

Abstract

Supraventricular tachycardia (SVT) is a prevalent cardiac arrhythmia requiring rapid and effective intervention. Landiolol, a highly selective, ultra-short acting, beta-1 adrenergic receptor blocker, has recently received FDA approval for short-term ventricular rate control in adults with SVT, including atrial fibrillation and atrial flutter. Its rapid onset and hemodynamic stability make it a valuable addition to acute cardiac care. Data from clinical trials, systematic reviews, and real-world studies were analyzed to evaluate landiolol’s role in SVT management. It effectively controls the ventricular rate in SVT. The drug exhibited a favourable safety profile and is better suited for rate control rather than arrhythmia termination when compared to adenosine. Its utility in managing perioperative atrial fibrillation, critically ill patients, and those with respiratory conditions makes it a valuable therapeutic option. Future research should explore its role in Indian demographics to optimize its clinical use.

Metrics

Metrics Loading ...

References

Nasoufidou A, Papazoglou AS, Stachteas P, Karagiannidis E, Samaras A, Alexiou S, et al. Intravenous Landiolol for Rate Control in Supraventricular Tachyarrhythmias in Patients with Left Ventricular Dysfunction: A Systematic Review and Meta-Analysis. J Clin Med. 2024;13(6):1683. DOI: https://doi.org/10.3390/jcm13061683

Syed YY. Landiolol: A Review in Tachyarrhythmias. Drugs. 2018;78(3):377-88. DOI: https://doi.org/10.1007/s40265-018-0883-9

Research C for DE and Novel Drug Approvals for 2024. FDA. 2024. Available at: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024. Accessed on 6 January 2025.

Floria M, Oancea AF, Morariu PC, Burlacu A, Iov DE, Chiriac CP, et al. An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation. Pharmaceutics. 2024;16(4):517. DOI: https://doi.org/10.3390/pharmaceutics16040517

Si X, Yuan H, Shi R, Song W, Guo J, Jiang J, et al. Comparison of the efficacy and safety of Landiolol and Esmolol in critically ill patients: a propensity score-matched study. Ann Intensive Care. 2025;15(1):5. DOI: https://doi.org/10.1186/s13613-024-01418-8

Yoneyama F, Tokunaga C, Kato H, Nakajima T, Mathis BJ, Sakamoto H, et al. Landiolol Hydrochloride Rapidly Controls Junctional Ectopic Tachycardia After Pediatric Heart Surgery. Pediatr Crit Care Med. 2018;19(8):713. DOI: https://doi.org/10.1097/PCC.0000000000001573

Alexandru MG, Niewald P, Krüger S, Borgstedt R, Whitehouse T, Singer M, et al. Mortality in septic patients treated with short-acting betablockers: a comprehensive meta-analysis of randomized controlled trials. Crit Care. 2024;28:392. DOI: https://doi.org/10.1186/s13054-024-05174-w

Aoyama H, Otsuka Y, Aoyama Y. Landiolol infusion during general anesthesia does not prevent postoperative atrial fibrillation in patients undergoing lung resection. Gen Thorac Cardiovasc Surg. 2016;64(12):735-41. DOI: https://doi.org/10.1007/s11748-016-0707-3

Ferraris A, Jacquet-Lagrèze M, Cazenave L, Fornier W, Jalalzai W, Rousseau-Saine N, et al. Microcirculatory effects of landiolol: a double-blind, randomised, controlled study after cardiac surgery. Br J Anaesth. 2021;126(6):e212-4. DOI: https://doi.org/10.1016/j.bja.2021.03.013

Levy B, Slama M, Lakbar I, Maizel J, Kato H, Leone M, et al. Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review. J Clin Med. 2024;13(10):2951. DOI: https://doi.org/10.3390/jcm13102951

Kowalik K, Silverman M, Oraii A, Conen D, Belley-Côté EP, Healey JS, et al. Landiolol for perioperative atrial tachyarrhythmias in cardiac and thoracic surgery patients: a systematic review and meta-analysis. Br J Anaesth. 2024;133(1):222-5. DOI: https://doi.org/10.1016/j.bja.2024.03.036

Sato R, Messina S, Hasegawa D, Santonocito C, Scimonello G, Sanfilippo G, et al. Mortality in Patients with Sepsis Treated with Esmolol or Landiolol: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis. Chest. 2025;167(1):121-38. DOI: https://doi.org/10.1016/j.chest.2024.08.020

Hasegawa D, Sato R, Prasitlumkum N, Nishida K, Takahashi K, Yatabe T, et al. Effect of Ultrashort-Acting β-Blockers on Mortality in Patients with Sepsis with Persistent Tachycardia Despite Initial Resuscitation: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Chest. 2021;159(6):2289-300. DOI: https://doi.org/10.1016/j.chest.2021.01.009

Miyawaki IA, Gomes C, Caporal S, Moreira V, Marques RI, de Souza IAF, et al. The Single-Syringe Versus the Double-Syringe Techniques of Adenosine Administration for Supraventricular Tachycardia: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs Drugs Devices Interv. 2023;23(4):341-53. DOI: https://doi.org/10.1007/s40256-023-00581-w

Krumpl G, Ulč I, Trebs M, Kadlecová P, Hodisch J, Maurer G, et al. Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites. J Cardiovasc Pharmacol. 2018;71(3):137-46. DOI: https://doi.org/10.1097/FJC.0000000000000554

Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, et al. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2020;8(9):863-72. DOI: https://doi.org/10.1016/S2213-2600(20)30037-0

Sezai A, Osaka S, Yaoita H, Ishii Y, Arimoto M, Hata H, et al. Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: Prevention of Atrial Fibrillation After Cardiac Surgery with Landiolol Hydrochloride for Left Ventricular Dysfunction (PLATON) trial. J Thorac Cardiovasc Surg. 2015;150(4):957-64. DOI: https://doi.org/10.1016/j.jtcvs.2015.07.003

Miyamoto M, Osawa K, Miyoshi T, Mori A, Yoshikawa M, Oka T, et al. Efficacy and Safety of Early Intravenous Landiolol on Myocardial Salvage in Patients with ST-segment Elevation Myocardial Infarction before Primary Percutaneous Coronary Intervention: A Randomized Study. Acta Med Okayama. 2021;75(3):289-97.

Krumpl G, Ulc I, Trebs M, Kadlecová P, Hodisch J. Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group. Eur J Clin Pharmacol. 2017;73(4):417-28. DOI: https://doi.org/10.1007/s00228-016-2176-0

Krumpl G, Ulc I, Trebs M, Kadlecová P, Hodisch J. Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2016;92:64-73. DOI: https://doi.org/10.1016/j.ejps.2016.06.022